Elixir, a pharmacy benefits and services company, recently selected Maxor Specialty Pharmacy as the exclusive Cystic Fibrosis (CF) provider in its industry leading, Best-in-Class (BIC) specialty pharmacy network.
Elixir’s BIC Network selects the best specialty partners across different disease states to provide treatment, individualized care and continuous member support throughout their treatment journey.
Maxor Specialty specializes in rare diseases like CF and is one of four pharmacies in the U.S. to have access to all medications approved for cystic fibrosis, including the triple combination therapy Trikafta, as well as Kalydeco, Orkambi, and Symdeko, all manufactured by Vertex Pharmaceuticals (Vertex).
Vertex is the clear market leader for global cystic fibrosis treatments. Vertex has established itself as the leading player due to its high-caliber drugs and sole focus on cystic fibrosis.
Maxor Specialty Pharmacy will provide Elixir CF patients with case management, education, such as how to clean and maintain their equipment, and fulfill their prescriptions.
Elixir provides specialty pharmacy services to those who require specialty medications, injectable pharmaceuticals and complex treatment regimens. Elixir offers a broad range of comprehensive care programs:
- Disease State Education and Monitoring
- Injection Training and Technique
- Side Effect Management Strategies
- Medication Counseling Services
Takeaway: Maxor Specialty Pharmacy will offer access to its Cystic Fibrosis Center of Excellence to Elixir’s members